Budget Impact of Intravenous Iron Therapy with Ferric Carboxymaltose in Patients with Chronic Heart Failure with Reduced Ejection Fraction (HFrEF) and Iron Deficiency in Switzerland

AIMS: A budget impact analysis compared treating patients with heart failure (HF) and reduced ejection fraction (HFrEF) and iron deficiency (ID) in Switzerland with intravenous ferric carboxymaltose (FCM) or placebo. METHODS: Clinical data from four international randomized trials showed that FCM ve...

Descripción completa

Detalles Bibliográficos
Autores principales: Brock, Elisabeth, Moschovitis, Giorgio, Maeder, Micha T., Pfister, Otmar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9440178/
https://www.ncbi.nlm.nih.gov/pubmed/35687248
http://dx.doi.org/10.1007/s41669-022-00341-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9440178/
https://www.ncbi.nlm.nih.gov/pubmed/35687248
http://dx.doi.org/10.1007/s41669-022-00341-7

Ejemplares similares